Teva Pharmaceutical Industries Ltd. — Director's Dealing 2021

Jun 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2021-06-14

Reporting Person: Halfon Jean Michel (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-14	Restricted Share Units	$	A	14479	Acquired		Ordinary Shares (14479)	Direct

Footnotes

F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022.

F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.